The Capsule Endoscopy Market is strongly influenced by the rising geriatric population, who are at a higher risk for GI-related chronic conditions and colorectal cancers. However, 2025 has also marked a significant expansion into the Pediatric segment. In January 2025, the FDA cleared the CapsoCam Plus for use in children as young as two years old, providing a vital, sedation-free diagnostic option for pediatric GI specialists.

The rising global burden of Inflammatory Bowel Disease (IBD) is another massive driver. With IBD cases expected to rise significantly by 2035, healthcare systems are increasingly adopting "capsule-first" protocols for monitoring disease progression. These devices allow for frequent, painless check-ups that improve patient compliance and enable early intervention, ultimately reducing the total cost of long-term chronic care management.

People Also Ask:

• Why is capsule endoscopy preferred for pediatric patients?

• How many people are living with IBD globally in 2025?

• Does capsule endoscopy help in the early detection of colorectal cancer?